Our Latest Pharmaceutical Jobs – 25.6.2012

Looking for a job in the Pharmaceutical Industry? Please click on the links below to find out about our latest pharmaceutical jobs new in this week:

New pharmaceutical roles in the UK and Europe:

Director, CMC, Regulatory Affairs

Documentation Specialist in Switzerland

Clinical Safety Scientist – Contract

Biomedical Data Statistician in Swavesey

Technical Regulatory Officer in Switzerland

Clinical Data Manager

Hub Labeling Manager in Surrey

Medical Director – CNS

Clinical Study Specialist

Senior Analyst – Regulatory Compliance

Snr Medical Advisor – Haematology

Register your CV with CK Clinical

Not quite what you’re looking for? Click here to register your CV with CK Clinical today.

Once registered, one of our specialist Pharmaceutical Recruitment Consultants will be in contact to discuss your requirements and any relevant pharmaceutical jobs we are recruiting for at the moment. Good luck with your job hunt!

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , ,

Our Latest Pharmaceutical Jobs – 19.6.2012

Looking for a job in the Pharmaceutical Industry? Please click on the links below to find out about our latest pharmaceutical jobs new in this week:

Clinical:

Clinical Study Manager

Medical Information Manager

Clinical Operations Manager, Oncology

Biometrics:

Senior Business Analyst – Germany

Contract Statistical Programmer

Contract Biostatistician

Regulatory Affairs Jobs:

Senior Manager, Regulatory Affairs, CMC

Pharmaceutical:

Pharmacovigilance Standards Officer

PV Project Manager

Pharmacovigilance Manager

Senior Director, Human Resources

Senior Pharmacovigilance Scientist

Senior Director, Finance

Associate Director of PV

Register your CV with CK Clinical

Not quite what you’re looking for? Click here to register your CV with CK Clinical today.

Once registered, one of our specialist Pharmaceutical Recruitment Consultants will be in contact to discuss your requirements and any relevant pharmaceutical jobs we are recruiting for at the moment. Good luck with your job hunt!

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , , ,

Astellas and DNDi work on tropical disease research

Pharma Times has reported that Astellas Pharmaceuticals has announced an agreement with the Drugs for Neglected Diseases initiative (DNDi) to collaborate on drug discovery research for three neglected tropical diseases

The 3 neglected tropical diseases are leishmaniasis, Chagas disease and sleeping sickness. These 3 together affect nearly 10 million people worldwide

Under the agreement, Astellas will provide DNDi with a selection of original compounds. These will be screened at the Swiss Tropical and Public Health Institute in Switzerland

Executive Director of DNDi, Dr Bernard Pécoul, said “We welcome Astellas as a new partner both in the field of NTDs and as part of a product development partnership. In the field of neglected diseases, and particularly for the most neglected – leishmaniasis, Chagas disease, and sleeping sickness – this new partnership reinforces the critical mass of engaged actors necessary to address urgent patient needs”

Are you looking for a new clinical job? Click here to see our latest clinical jobs

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , ,

Advances in medicine helps a 10 year old girl

BBC News has reported that a 10-year-old girl has had a major blood vessel in her body replaced with one grown with her own stem cells according to Swedish doctors

A team led by Professor Suchitra Sumitran-Holdgersson of the University of Gothenburg successfully transplanted a vein made from a 10-year-old girl’s own stem cells into her body.  It is the first time such an operation has been reported and marks an important step in the practical ability of doctors to use stem cells to grow replacement cells for damaged or diseased tissue.

Professors Martin Birchall and George Hamilton, from University College London, said: “The young girl was spared the trauma of having veins harvested from the deep neck or leg with the associated risk of lower limb disorders. Birchall and Hamilton also said the procedure may get cheaper as medical companies start producing protein scaffolds from human and animal sources more efficiently. They concluded that Prof Sumitran-Holdgersson’s work was promising, but it needed to be properly tested in full clinical trials if such regenerative medicine treatments were to become widely used and accepted.

Are you looking for a new clinical job? Click here to see our latest clinical jobs

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , ,

Roche Personalised Breast Cancer Drug Approved

As reported by the PharmaTimes, Roche’s new personalised medicine for HER2-positive metastatic breast cancer has been approved by the US Food and Drug Administration (FDA).

Roche Personalised Breast Cancer Drug Approved by FDAThe drug, called Perjeta combines Roche’s Herceptin drug along with chemotherapy. It works by targeting a different part of the HER-protein than Herceptin does. This resulted in a further reduction in growth of the HER2-positive breast cancer cells and prevents them from surviving.

Approval from the FDA came as a result of a successful Phase III study which found that patients who took a combination of Perjeta, Herceptin and docetaxel lived 6.1 months longer without their cancer getting worse.

Speaking of the FDA approval, Chief Medical Officer and Head of Global Product Development at Roche, Hall Barron, stated, “Today’s approval of Perjeta is an important advance in the treatment of HER2-positive

metastatic breast cancer.  Perjeta attacks HER2-positive tumours differently than Herceptin. Based on the way the two medicines work together, the combination plus chemotherapy can prolong the time before this aggressive cancer worsens compared to Herceptin and chemotherapy alone. We are very pleased to see our efforts in studying the science of HER2 translate into another personalized medicine.”

Search our Pharmaceutical Jobs in the UK and Europe

 

Are you looking for a job in the Pharmaceutical Industry?

Click here to search our pharmaceutical jobs online now.

Posted in Industry News, NewsTagged in , , , , , , , , ,

J&J’s new diabetes drug exceeds previous therapies

Reuters have reported that an experimental treatment for type 2 diabetes developed by Johnson & Johnson demonstrated greater reduction in blood sugar than older therapies.

The J&J drug, canagliflozin, also showed considerably greater weight loss than both of the other drugs and far fewer incidents of hypoglycemia, or potentially dangerous drops in blood sugar levels.  Canagliflozin, belongs to a new class of diabetes treatments called SGLT2 inhibitors that work by blocking reabsorption of glucose by the kidney and increases glucose excretion in the urine to lower blood sugar.

This information came from date collected in two 52-week studies. The date was presented on Saturday at the American Diabetes Association (ADA) meeting in Philadelphia, are part of a massive approval application J&J submitted to the U.S. Food and Drug Administration last week that comprised nine separate Phase III trials involving more than 10,000 patients

If approved it would be J&J’s first diabetes medicine.

Are you looking for a new position in the Pharmaceutical Industry? Click here to search our current pharmaceutical jobs online now.

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , ,

Novartis drug Ilaris can reduce arthritis outbreaks

Reuters reported that the Swiss drug maker Novartis released new positive data from two studies of Ilaris, which showed that patients suffering from the most severe form of childhood arthritis were less likely to experience a flare up in the disease.

Systemic juvenile idiopathic arthritis (SJIA) affects less than one child per 100,000. It causes inflammation affecting the whole body, which can involve skin rashes, fever, joint pain and swelling.

Novartis said that the results of a final-stage study showed 62% of patients with SJIA who received Ilaris became symptom-free against 32 percent of those taking a placebo. The results also showed that one third of patients could stop taking steroids within five months of using the drug.

Novartis also said it was on track to submit the drug for regulatory approval for SJIA in both Europe and the United States, based on data from this and other late-stage phase III trials presented last year.

Are you looking for a new position in the Pharmaceutical Industry? Click here to search our current pharmaceutical jobs online now.

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , , , , , , , , , , , , , , , ,

Roche & Bristol Myers-Squibb – cancer treatments

As reported by Cancer Research UK, the pharmaceutical companies Roche and Bristol Myers-Squibb are working with Cancer Research to plan global trials to develop targeted cancer treatments.

The trials will test for a number of gene faults that are linked to cancer. The results will then be compared to the results of treatment to specific faults within cancer cells.

Roche and Bristol Myers-Squibb work with Cancer Research on targeted cancer treatmentsSwiss-based pharmaceutical company, Roche will aim to determine whether or not their targeted skin cancer drug, vemuranfenib is effective for a range of difference cancer. Whereas Bristol-Myers Squibb is seeking health authority and ethics approval.

Michelle Rashford, medical director, Roche UK said: “The stratified medicines programme run by Cancer Research UK is an exciting initiative, as the opportunity to test tumour samples for a range of biomarkers is an important step in the continued development of personalised medicines.  Our VE-Basket study of vemurafenib in patients with V600 mutation positive cancers across different disease areas will allow us to identify patients that may benefit from treatment, and get closer to the goal of truly targeted medicines that provide better patient outcomes, reduce unnecessary side effects and ultimately deliver life-saving and life-prolonging treatments.”

Looking for a job in the Pharmaceutical Industry? Click here to search our pharmaceutical jobs online now.

Posted in Industry News, NewsTagged in , , , , , , , , , , , , ,

Bayer Healthcare and Covance announce a long term partnership

Pharmatimes reported that Bayer HealthCare has announced a long-term strategic partnership for clinical drug development with US-based provider CovanceBayer and Covance will work on clinical drug development, including research and development related to Phase II-IV clinical studies and central laboratory services.

Bayer Healthcare  aims to better leverage Covance’s broad range of experience and services across the R&D portfolio to attain best in class operational delivery, efficiency and quality while also delivering significant financial benefits to both organizations.

John Watson, president, strategic partnering, and chief commercial officer at Covance said “We are extremely proud to have established an enduring relationship with Bayer HealthCare built on trust and proven performance that is now elevating to a strategic partnership,”

Are you searching for a new clinical job? Click here to see our latest clinical jobs

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , , , , , ,

£73 million centre for translational medicine opens at Imperial College London

As reported by PharmaTimes, a major new £73 million research facility at Imperial College London for Translational and Experimental Medicine opened yesterday.

The Imperial Centre for Translational and Experimental Medicine (ICTEM) combines laboratory space for up to 450 scientists with a dedicated facility for evaluating and developing new medical treatments through clinical trials.

The six-storey building is located on Imperial’s Hammersmith Campus, alongside Hammersmith Hospital. The upper floors of the building constitute one of the largest cardiovascular research facilities in Europe, including the headquarters of the British Heart Foundation Centre of Research Excellence at Imperial.

Chancellor George Osborne who opened the facility said: “It’s an honour to open this new Imperial Centre for Translational and Experimental Medicine. It is what this country’s vision for the future of life sciences is all about. This new Centre rises to the challenge of ensuring we remain a world leader in life sciences. The future is academic research, clinical practice and industrial application coming together”

Are you searching for a new clinical job? Click here to see our latest clinical jobs

Follow us on Twitter @CKClinical to receive more industry news and CK jobs of the week updates

Posted in Industry News, NewsTagged in , , , , , , , , ,